Castle Biosciences Unveils New Data Showing DecisionDx-Melanoma Improves Sentinel Lymph Node Biopsy Decision Making
Reuters
Nov 14, 2025
<a href="https://laohu8.com/S/CSTL">Castle Biosciences</a> Unveils New Data Showing DecisionDx-Melanoma Improves Sentinel Lymph Node Biopsy Decision Making
Castle Biosciences Inc. has announced new data from clinical studies demonstrating the value of its DecisionDx®-Melanoma test in guiding sentinel lymph node biopsy (SLNB) decisions and predicting recurrence risk in patients with cutaneous melanoma. The findings will be presented in two oral sessions at the 2nd European Congress on Dermato-Oncology, scheduled for November 17-18, 2025, in Paris, France. A multicenter study involving 810 patients with early-stage, SLN-negative cutaneous melanoma found that the DecisionDx-Melanoma test serves as an independent predictor of recurrence and improves risk assessment beyond American Joint Committee on Cancer (AJCC) staging alone. Patients with high-risk (Class 2B) results showed significantly lower five-year recurrence-free survival compared to those with lower-risk classifications. The addition of DecisionDx-Melanoma results to AJCC staging increased prognostic accuracy, supporting its potential to enhance surgical planning and patient management.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9575655-en) on November 14, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.